Latest Developments in Viral and Non-Viral Vector Manufacturing

CELL AND GENE THERAPY INSIGHTS

February 2018

Latest Developments in Viral and Non-Viral Vector Manufacturing

Download PDF

Expert Insight

Downstream bioprocessing of AAV vectors: industrial challenges & regulatory requirements

Downstream bioprocessing of AAV vectors: industrial challenges & regulatory requirements

Matthias Hebben

Regulatory pathway on the manufacture & quality control of recombinant adeno-associated virus vectors

Regulatory pathway on the manufacture & quality control of recombinant adeno-associated virus vectors

Terence Flotte, Allison Keeler

Analytical approaches to characterize AAV vector production & purification: Advances and challenges

Analytical approaches to characterize AAV vector production & purification: Advances and challenges

Fabien Dorange, Christine Le Bec

Innovator Insight

Addressing scaling-up limitations: optimized PEI-mediated production of clinical grade viral vectors

Addressing scaling-up limitations: optimized PEI-mediated production of clinical grade viral vectors

Alengo Nyamay’Antu, Valérie Kedinger, Patrick Erbacher

Overcoming Downstream Purification Challenges for Viral Vector Manufacturing: Enabling Advancement of Gene Therapies in the Clinic

Overcoming Downstream Purification Challenges for Viral Vector Manufacturing: Enabling Advancement of Gene Therapies in the Clinic

O Terova, P Hermans, J Rooij et al.

Interview

Merits of non-viral cellular engineering versus viral cellular engineering

Merits of non-viral cellular engineering versus viral cellular engineering

Addressing the Challenges of Commercial-Scale Viral Vector Production

Addressing the Challenges of Commercial-Scale Viral Vector Production

Webinars

Commercial-scale viral vector manufacture: technical challenges & strategic implications

Commercial-scale viral vector manufacture: technical challenges & strategic implications

M Kelly, C Glover, R Snyder

14 February 2018